AbbVie Inc (ABBV)vsAclarion Inc (ACON)
ABBV
AbbVie Inc
$294.90
+3.09%
HEALTHCARE · Cap: $521.11B
ACON
Aclarion Inc
$1.74
-1.14%
HEALTHCARE · Cap: $5.62M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 78803767% more annual revenue ($66.01B vs $83,770). ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
ACON
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$294.90
$138.06 premium
Intrinsic value data unavailable for ACON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 30.5% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while ACON is a hypergrowth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.21 — expect wider price swings.
ACON is growing revenue faster at 30.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 33/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is an innovative healthcare technology company focused on transforming the diagnosis and management of musculoskeletal conditions through advanced non-invasive imaging and data analytics. Leveraging machine learning capabilities, Aclarion provides healthcare professionals with actionable insights that improve clinical outcomes while optimizing cost-effective treatment pathways. As a key player in the digital health arena, the company is positioned to address the growing demand for effective diagnostic solutions, thereby enhancing patient care and management in a rapidly evolving healthcare environment. Aclarion's commitment to improving patient outcomes places it at the forefront of future healthcare delivery advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?